Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BRGO latest news https://www.otcmarkets.com/stock/BRGO/news
Market Cap Market Cap
276,683 08/12/2020
Outstanding Shares 42,566,640
He added, "I appreciate all the support from our shareholders and wishing all to stay safe through these unprecedented times, with a bright future is ahead".
"The Company continues to pursue additional financing opportunities.? Financing discussions have been taking place with various parties, but the Company has no firm commitment from any party to provide additional funding at this time."
"While the impact of the pandemic still provides some uncertainty, we continue to be excited about our future. The Company has leveraged itself such that as sales increase a larger portion of dollars will flow to the bottom line."
We also intend to complement our own quality-designed jewelry with other products and our own specially-designed handbags. This is in line with our strategy and belief that a brand name can create an association with innovation, design and quality which helps add value to the individual products as well as facilitate the introduction of new products with higher profit margins.
Our branded product lines are products and/or collections designed by our designer and CEO Berge Abajian and will be the centerpiece of our retail stores.
The Company continues to position itself for the future to take advantage of the Bergio brand and establish a chain of retail stores worldwide.
However, we are expanding our online presence and have been experiencing some positive results, which we believe will be reflected in the second quarter results, but it is too early to assess the real impact.
Mr. Berge Abajian, President & CEO stated "this was a difficult quarter and our business has been impacted by the pandemic.
Non-GAAP Adjusted EBITDA showed a loss of only $39,411 for the quarter ended March 31, 2020 as compared to a loss of $35,448 for the same period last year.
Net loss was $1,470,901 for the quarter ended March 31, 2020 as compared to a net loss of $90,848 for the quarter ended March 31, 2019. The year 2020 was impacted by a number of non-cash items, mostly the change in the fair value of derivative due to the higher stock price at March 31, 2020.
Operating loss was $179k for the quarter ended March 31, 2020, excluding the non-cash consulting expenses our operating loss would have been $48K as compared to $62k for the quarter ended March 31, 2019.
Operating expenses increased 42% to $228k as a result of non-cash consulting expenses to provide brand awareness for the Company's new line of fashion accessories and to develop strategies for global expansion.
Gross profit as a percentage of sales remains strong at 65.1%.
Revenues declined 45% for the quarter ended March 31, 2020 as compared to same period last year. The Company's retail operations were shut down as a result of COVID-19 for one-third of the quarter, but business was already declining because of the pandemic.
But wouldnt be bad to load some before the volume comes in
Agree with you i may jump in if i see a reversal on volume
Great news this AM
Lets see if can see another huge volume soon
Break of 0.02 would trigger this stock
Several cities, including Denver and Oakland, Calif., have decriminalized certain natural hallucinogenics including "magic mushrooms."
A report titled Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development found that such treatments have ““positive long-term mental health consequences, rather than daily neurochemical corrections in brain dysfunctions,” meaning they may help treat conditions better than pharmaceuticals, as noted by Leafly.
All thanks to reports that show psychedelics have therapeutic benefits. For example, researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post. Researchers from the University of California David found that micro-dosing with psychedelic drugs for a prolonged period of time showed promise. “Our study demonstrates that psychedelics can produce beneficial behavioral effects without drastically altering perception, which is a critical step towards producing viable medicines inspired by these compounds," said David Olson of UC Davis, as quoted by Esquire.
Denver, Oakland, and Santa Cruz voted to decriminalize mushrooms. Washington, D.C. just took a major step toward adding legalization to the Nov. 2020 ballot. Chicago city leaders passed a resolution supporting scientific and medicinal research, with a goal of decriminalization. Vermont lawmakers filed a bill to decriminalize it, as well. Even Oregon is pushing to legalize psilocybin mushrooms for therapeutic purposes.
Researchers in Switzerland found in 2014 that LSD can be helpful for patients dealing with end-of-life anxiety related to a terminal illness. The same sort of conclusion has been drawn for psilocybin. Psilocybin has also proven useful for treating severe depression. MDMA has shown great promise for treating PTSD, when used alongside psychotherapy. All of the drugs remain illegal in the United States, and there has been little effort to change that.
Even if marijuana is legalized throughout the United States, there will still be numerous drugs in this country that remain very much illegal, and Americans will suffer because of this. Drugs like psilocybin mushrooms, LSD and MDMA have all demonstrated great potential when it comes to medical benefits, and shown little potential for harm. Still, the idea of legalizing those drugs any time soon seems as likely as Donald Trump hosting a quinceañera.
Summary: Salon speaks with MAPS Founder Rick Doblin, Ph.D., about the potential medical benefits of using LSD, psilocybin, or MDMA as adjuncts to psychotherapy. "LSD, psilocybin and MDMA, when combined with psychotherapy, have tremendous medical potential for treating psychiatric illnesses in people for whom other treatments have failed," explains Doblin. "These psychedelic drugs need to be legalized, both through scientific drug development studies designed to obtain FDA approval for prescription use and through political means so that they are legalized for non-medical purposes like personal growth, spirituality, couples therapy, creativity, innovation, and celebratory experiences."
looks like Canadians are all over psychedelic s
Only great coverage about psychedelic lately
Well they talk about it only on huge volume day
I like this one wonder why no one is talking about it
So do you guys think it's heading over 0.02 this week?
Been flat for a few weeks and it held well
Chart doesn't look bad at all
Will try to get 50k more if doesn't gap up tomorrow
Only grabbed 80k shares
And already being covered and endorsed by many rich and famous people
Just getting started